Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLYM116 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CLYM116 | EXPERIMENTAL | Subcutaneous (SC) injection of CLYM116 |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous (SC) injection of placebo |
| Name | Type | Description |
|---|---|---|
| CLYM116 | DRUG | CLYM116 to be administered by SC injection |
| Placebo | DRUG | Placebo solution to be administered at a matching volume by SC injection |
Inclusion Criteria: * Healthy adult males and females aged 18-60 years, inclusive * Body mass index (BMI) between 18 and 32 kg/m² and weight between 45 and 110 kg * Clinically normal medical history, physical exam, ECG, and laboratory results (or abnormalities deemed not clinically significant) * W...
CLYM116 is an investigational small molecule drug being developed by Climb Bio, Inc. It is currently in Phase 1 clinical development. The specific diseases or conditions it is intended to treat have not been disclosed.
CLYM116 targets APRIL, a protein that is part of the tumor necrosis factor ligand family. By binding to APRIL, CLYM116 is designed to modulate its activity. APRIL is a protein target, and CLYM116 is a small molecule therapeutic.
CLYM116 is being developed by Climb Bio, Inc., a biotechnology company whose common stock trades on the Nasdaq under the ticker symbol CLYM.
CLYM116 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency.
CLYM116 is being evaluated in a Phase 1 clinical trial, NCT07248865, titled "A Phase 1 Study of CLYM116 in Normal Healthy Volunteers." The trial is currently recruiting and is expected to enroll 48 healthy adult participants in Australia.
Yes, the Phase 1 trial of CLYM116, NCT07248865, is a randomized, double-blind, placebo-controlled study. It is enrolling healthy volunteers aged 18 years and older, regardless of sex.